| Objective:To observe the clinical curative effect of herbal paste in wintertime combined with Sanfu paste in the treatment of patients with chronic obstructive pulmonary disease(COPD)in the stable phase,to further retrospectively analyze the efficacy of Sanfu paste alone in the treatment of patients with COPD,and examine the association between the length of Sanfu paste and the efficacy.Methods:1 The study subjects were from the respiratory department of Jiangsu Provincial Hospital of Traditional Chinese Medicine(TCM)and the 58 patients,with stable COPD who met the inclusion criteria were divided into treatment group(28 cases)and control group(30 cases).The treatment group was treated with herbal paste in wintertime and Sanfu paste on the basis of routine treatment of western medicine.The control group only received conventional treatment with western medicine.The scores of TCM syndromes,the scores of St George's respiratory questionnaire(SGRQ),the scores of COPD assessment test(CAT),lung function(FEV1%,FEV1/FVC),the 6-minute walking distance(6MWD),and the blood oxygen saturation(Sp02%)were performed before treatment and 12 months afte r treatment to assess the clinical efficacy of plaster combined with Sanfu paste in the treatment of COPD patients.Meanwhile,the information collected also included the frequency of exacerbations,the number of hospitalizations and occurrence of adverse events during the observation period before and after treatment.2 According to the retrospective study,182 patients with stable COPD who met the inclusion criteria in the Department of Respiratory,Jiangsu Provincial Hospital of TCM from 2015 to 2018.55 patients who had not been treated with Sanfu paste before 2018 as a control group,and the remaining 127 patients who underwent Sanfu paste were included in the observation group.Among them,42 patients who were treated with Sanfu paste in 2015,2016,and 2017 were set as the three-year group,43 patients treated with Sanfu paste in 2016 and 201 7were set as the two-year group,and only 42 patients who were treated with Sanfu paste in 2017 were set as the one-year group.Lung function(FEV1%,FEV1/FVC),the frequency of exacerbations,the number of hospitalizations,the scores of SGRQ and CAT for patients were evaluated to assess the efficacy of Sanfu paste.Examine the association between the length of Sanfu paste and the efficacy.Results:1 After treatment,the TCRM symptom scores of the treatment group and the control group improved(P<0.05).The treatment group was better than the control group(P<0.05).The frequency of exacerbations in the treatment group(1.44610.809)was lower than before(2.83910.789)(P<0.05).The frequency of exacerbations in the control group(2.033±0.533)was lower than before(2.650±0.721)(P<0.05).The treatment group was better than the control group(P<0.05).The number of hospitalizations in the treatment group(1.036±0.407)was lower than before(2.3211±0.723)(P<0.05).The number of hospitalizations in the control group(1.667±0.674)was lower than before(2.167±0.834)(P<0.05).The treatment group was better than the control group(P<0.05).The SGRQ scores(46.436±13.282)in the treatment group were improved compared with the previous(59.096±12.818)(P<0.05).The SGRQ scores(53.275±10.875)in the control group were improved compared with the previous(57.296±9.690)(P<0.05).The treatment group was better than the control group(P<0.05).The CAT scores(20.071±5.981)in the treatment group were improved compared with the previous(23.821±6.992)(P<0.05).The CAT scores(23.533±6.090)in the control group were improved compared with the previous(25.333±5.579)(P<0.05).The treatment group was better than the control group(P<0.05).After treatment,the total effective rate of the treatment group was 85.71,the total effective rate of the control group was 66.67.The treatment group was superior to the control group(P<0.05).There was no significant difference in lung function FEV1%,FEV1/FVC(47.760±12.993,57.001±8.343)compared with the previous(48.225±7.291,56.604±7.758)in the treatment group(P>0.05).There was no significant difference in lung function FEV1%,FEV1/FVC(49.134±11.750,57.366±7.474)compared with the previous(48.460±12.937,57.848±7.975)in the control group(P>0.05).There was no statistically significant difference between the two groups after treatment(P>0.05).6MWD(272.00±94.88m)increased(P<0.05)in the treatment group compared with the previous(228.43±73.57m).6MWD(246.67±85.83m)increased(P<0.05)compared with the former(224.93±72.67m)after treatment in the control group.There was no statistical difference between the treatment group and the control group(P>0.05).There was no significant difference in SpO2%(92.00±2.89)compared with the previous(91.46±3.14)in the treatment group(P>0.05).There was no significant difference in SpO2%(91.40±3.15)compared with the former(91.77±2.91)after treatment(P>0.05).There was no statistically significant difference between the two groups after treatment(P>0.05).No serious adverse reactions or accidents occurred in either group.2 In the observation group,the FEV1%(42.04±1 7.29,46.09±15.53,50.59±15.81)and the pre-treatment(43.32±15.18,45.02±12.23,49.93±11.24)were observed in the one-year group,the two-year group and the three-year group.The difference was not statistically significant(P>0.05).There was no significant difference between the observation group and the control group before and after treatment(P>0.05).In the observation group,the FEV1/FVC(54.68±16.09,58.07±12.43,57.03±11.98)and the pre-treatment(54.68±16.09,55.31±12.32,57.36±12.09)were observed in the one-year group,the two-year group and the three-year group.The difference was not statistically significant(P>0.05).There were no significant differences between the observation group and the control group before and after treatment(P>0.05).The frequency of exacerbations in the observation group in the one-year group,two-year group and three-year group(2.19±0.80,1.87±0.69,1.33±0.59)were lower than that before treatment(2.85±0.99,2.74±0.80,2.68±0.76)(P<0.01).After treatment,the two-year group compared with the one-year group,the three-year group compared with the one-year group,and the three-year group compared with the two-year group decreased(P<0.01).The number of hospitalizations in the observation group in the one-year group,two-year group and three-year group(1.70±0.84,1.57±0.90,1.11±0.56)were lower than that before treatment(2.27±0.86,2.28±0.84,2.11±0.78)(P<0.01).After treatment,the number of hospitalizations in the three-year group was lower than that in the one-year group,and the three-year group was lower than that in the two-year group decreased(P<0.01).The SGRQ scores of the observation group the two-year group and the three-year group(49.08±12.21,43,12±10.99)were lower than those in the control group(56.93±13.65)(P<0.01).The score of the two-year group was lower than that of the one-year group(55.88±11.54)(P<0.05).The score of the three-year group was lower than that of the two-year group and the one-year group(P<0.05).The scores of CAT in the observation group in the two-year group and the three-year group(25.49±6.15,22.12±6.63)were lower than those in the control group(28.96±6.34)(P<0.01).The score of the two-year group was lower than that of the one-year group(28.17±5.75)(P<0.05).The score of the three-year group was lower than that of the two-year group and the one-year group(P<0.05).Conclusions:Herbal paste in wintertime combined with Sanfu paste can reduce the frequency of exacerbations and the number of hospitalizations,improve clinical symptoms,the quality of life,and clinical application safety in patients with stable COPD.Further retrospective analysis of the efficacy of Sanfu paste alone in the treatment of patients with stable COPD,suggesting that Sanfu paste can reduce the frequency of exacerbations,the number of hospitalizations,improve the clinical symptoms of patients with stable COPD,the quality of life and the effect is more significant with the increase of treatment years. |
PDF Full Text Request